OptiNose GAAP EPS of -$0.17 in-line, revenue of $20.86M beats by $0.17M

• OptiNose press release (NASDAQ:OPTN): Q4 GAAP EPS of -$0.17 in-line.
• Revenue of $20.86M (-7.3% Y/Y) beats by $0.17M.
• The company expects XHANCE net revenues for the full year of 2023 to be between $62.0 to $68.0 million. XHANCE net revenues attributable to a launch as a treatment for patients with chronic sinusitis are not assumed in the full year 2023 guidance range. In addition, the Company's expectation for full year 2023 XHANCE net revenues includes its expectation that first quarter 2023 XHANCE net revenues will be approximately $10.0 million. The Company expects XHANCE average net revenue per prescription to be approximately $200 for full year 2023.